Bradley Canino
Stock Analyst at Stifel
(1.67)
# 3,439
Out of 5,111 analysts
89
Total ratings
35%
Success rate
-1.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Maintains: Buy | $46 → $38 | $15.30 | +148.37% | 4 | Dec 2, 2025 | |
| SNDX Syndax Pharmaceuticals | Reinstates: Buy | $44 | $20.37 | +116.00% | 7 | Sep 10, 2025 | |
| BDTX Black Diamond Therapeutics | Maintains: Buy | $16 → $15 | $2.79 | +437.63% | 5 | Mar 7, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Hold | $3 → $1.5 | $1.47 | +2.04% | 8 | Mar 7, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $23 → $19 | $11.92 | +59.40% | 2 | Feb 28, 2025 | |
| RLAY Relay Therapeutics | Maintains: Buy | $27 → $23 | $8.03 | +186.43% | 5 | Feb 27, 2025 | |
| ARVN Arvinas | Maintains: Buy | $63 → $51 | $12.58 | +305.41% | 6 | Feb 12, 2025 | |
| KURA Kura Oncology | Downgrades: Hold | $26 → $19 | $10.22 | +85.91% | 6 | Oct 14, 2024 | |
| CELC Celcuity | Maintains: Buy | $39 → $42 | $105.25 | -60.10% | 4 | Oct 7, 2024 | |
| SMMT Summit Therapeutics | Maintains: Buy | $25 → $40 | $17.57 | +127.66% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $135 | $104.72 | +28.92% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $9.38 | +113.22% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $4.30 | +132.56% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $1.40 | +614.29% | 17 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $99 | $96.93 | +2.14% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $2.47 | +466.80% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $55 | $89.68 | -38.67% | 4 | Feb 23, 2024 |
Janux Therapeutics
Dec 2, 2025
Maintains: Buy
Price Target: $46 → $38
Current: $15.30
Upside: +148.37%
Syndax Pharmaceuticals
Sep 10, 2025
Reinstates: Buy
Price Target: $44
Current: $20.37
Upside: +116.00%
Black Diamond Therapeutics
Mar 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $2.79
Upside: +437.63%
ALX Oncology Holdings
Mar 7, 2025
Maintains: Hold
Price Target: $3 → $1.5
Current: $1.47
Upside: +2.04%
Cullinan Therapeutics
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $19
Current: $11.92
Upside: +59.40%
Relay Therapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $27 → $23
Current: $8.03
Upside: +186.43%
Arvinas
Feb 12, 2025
Maintains: Buy
Price Target: $63 → $51
Current: $12.58
Upside: +305.41%
Kura Oncology
Oct 14, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $10.22
Upside: +85.91%
Celcuity
Oct 7, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $105.25
Upside: -60.10%
Summit Therapeutics
Sep 25, 2024
Maintains: Buy
Price Target: $25 → $40
Current: $17.57
Upside: +127.66%
Sep 16, 2024
Maintains: Buy
Price Target: $115 → $135
Current: $104.72
Upside: +28.92%
Sep 6, 2024
Initiates: Buy
Price Target: $20
Current: $9.38
Upside: +113.22%
Aug 8, 2024
Initiates: Buy
Price Target: $10
Current: $4.30
Upside: +132.56%
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $1.40
Upside: +614.29%
Jun 17, 2024
Maintains: Buy
Price Target: $90 → $99
Current: $96.93
Upside: +2.14%
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $2.47
Upside: +466.80%
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $89.68
Upside: -38.67%